Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic disease that is characterized by intestinal inflammation. Epithelial damage and loss of intestinal barrier function are believed to be the hallmark pathologies of the disease. In IBD, the resident and infiltrating immune cells consume much oxygen, render...
Saved in:
Main Authors: | Jie Lun (Author), Hongwei Zhang (Author), Jing Guo (Author), Mengchao Yu (Author), Jing Fang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
by: Jing Li, et al.
Published: (2022) -
Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
by: Li Zheng, et al.
Published: (2022) -
Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
by: Mengqiu Miao, et al.
Published: (2022) -
Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
by: Yu-Hsiang Chou, et al.
Published: (2023) -
Structure-Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
by: Andrey A. Poloznikov, et al.
Published: (2022)